

Obagi Medical Products, Inc.  
Form SC TO-T/A  
April 25, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE TO**  
**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**(AMENDMENT NO. 7)**

**OBAGI MEDICAL PRODUCTS, INC.**

**(Name of Subject Company (Issuer))**

**Odysseus Acquisition Corp.**

**a wholly owned subsidiary of**

**Valeant Pharmaceuticals International**

**a wholly owned subsidiary of**

**Valeant Pharmaceuticals International, Inc.**

**(Names of Filing Persons (Offerors))**

**COMMON STOCK, PAR VALUE \$0.001 PER SHARE**

**(Title of Class Of Securities)**

**67423R108**

Edgar Filing: Obagi Medical Products, Inc. - Form SC TO-T/A

(CUSIP Number of Class of Securities)

**Robert Chai-Onn**

**Executive Vice President, General Counsel and Corporate Secretary**

**Valeant Pharmaceuticals International, Inc.**

**2150 St. Elzéar Blvd. West**

**Laval, Quebec**

**Canada, H7L 4A8**

**(949) 461-6000**

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

*With copies to:*

**Stephen F. Arcano**

**Marie L. Gibson**

**Skadden, Arps, Slate, Meagher & Flom LLP**

**4 Times Square**

**New York, NY 10036**

**(212) 735-3000**

**CALCULATION OF FILING FEE**

**Transaction Valuation(1)**  
\$418,419,312

**Amount Of Filing Fee(2)**  
\$57,072.39

- (1) Estimated solely for purposes of calculating the filing fee. The transaction value was determined by multiplying (x) \$24.00 (i.e., the tender offer price) by 17,434,138, the estimated maximum number of shares of common stock of Obagi Medical Products, Inc. to be acquired in the tender offer.
- (2) The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for Fiscal Year 2013, issued August 31, 2012, revised October 2012, by multiplying the transaction value by 0.00013640.

## Edgar Filing: Obagi Medical Products, Inc. - Form SC TO-T/A

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$57,072.39

Filing Party: Odysseus Acquisition Corp., Valeant  
Pharmaceuticals International and Valeant  
Pharmaceuticals International, Inc.

Form or Registration No.: Schedule TO-T, Schedule TO-T/A Date Filed: March 26, 2013, April 4, 2013

“ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.  
Check the appropriate boxes below to designate any transactions to which the statement relates:

- third-party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: “

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

- Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
- Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 7 ( Amendment No. 7 ) amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission (the SEC ) on March 26, 2013 and amended on April 4, 2013 and April 5, 2013, April 12, 2013, April 22, 2013, April 23, 2013 and April 24, 2013 (as amended, the Schedule TO ) and relates to the offer of Odysseus Acquisition Corp., a Delaware corporation (the Purchaser ), to purchase all outstanding shares of common stock, par value \$0.001 (the Shares ), of Obagi Medical Products, Inc., a Delaware corporation ( Obagi ), at a price of \$24.00 per Share, net to the seller in cash, without interest (less any required withholding taxes) (the Offer Price ), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated March 26, 2013 (together with any amendments or supplements thereto, the Offer to Purchase ) and in the related Letter of Transmittal (together with any amendments or supplements thereto, the Letter of Transmittal and, together with the Offer to Purchase, the Offer ), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. The Purchaser is a wholly owned subsidiary of Valeant Pharmaceuticals International, a Delaware corporation ( VPI ), which is a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., a Canadian corporation ( Valeant ). This Amendment No. 7 is being filed on behalf of VPI, Valeant and the Purchaser.

All the information set forth in the Offer to Purchase, to the extent incorporated by reference therein, is hereby amended and supplemented as set forth below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Offer to Purchase.

**ITEM 11. ADDITIONAL INFORMATION**

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

The Offer expired at 12:00 midnight, New York City time, on April 25, 2013. The Depositary for the Offer has advised VPI and the Purchaser that, as of the expiration of the Offer, a total of 14,708,133 Shares had been validly tendered into and not withdrawn from the Offer, representing approximately 84.12% of the 17,484,138 outstanding Shares as of 12:00 midnight, New York City time, on April 25, 2013. Additionally, the Depositary has advised VPI and the Purchaser that an additional 938,189 Shares had been tendered by notice of guaranteed delivery. The Purchaser has accepted for payment all Shares validly tendered into the Offer and not properly withdrawn.

Pursuant to the terms of the Merger Agreement, the Purchaser intends to exercise its option to purchase at a purchase price of \$24.00 per Share directly from Obagi an additional number of Shares sufficient to give the Purchaser ownership of at least 90% of Obagi's then outstanding Shares (on a fully diluted basis), when combined with the Shares purchased by the Purchaser in the Offer.

Following the purchase of Shares in the Offer and the issuance of Shares pursuant to the Top-Up Option, the Purchaser will have sufficient voting power to approve the Merger without the affirmative vote of any other stockholder of Obagi. Accordingly, the Purchaser and VPI intend to consummate a short-form merger in which the Purchaser will merge with and into Obagi, with Obagi surviving the Merger and continuing as a wholly-owned subsidiary of VPI. As a result of the Merger, each Share issued and outstanding immediately prior to the Effective Time, other than (i) Shares owned, directly or indirectly, by VPI or the Purchaser immediately prior to the Effective Time or held by Obagi immediately prior to the Effective Time, all of which will be cancelled and cease to exist, and (ii) Shares held by stockholders of Obagi who properly exercised their appraisal rights under Section 262 of the DGCL, will be converted into the right to receive an amount of cash equal to the Offer Price, without interest (less any applicable withholding taxes). All Shares that are converted into the right to receive the Offer Price will be canceled and cease to exist. Promptly following consummation of the Merger, VPI intends to cause all Shares to be delisted from the Nasdaq and deregistered under the Exchange Act.

On April 25, 2013, Valeant issued a press release announcing the expiration and results of the Offer. The full text of the press release is attached as Exhibit (a)(5)(H) to the Schedule TO and is incorporated herein by reference.

**ITEM 12. EXHIBITS**

Item 12 of the Schedule TO is hereby amended and supplemented to add the following exhibit:

(a)(5)(H) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 25, 2013.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 25, 2013

**ODYSSEUS ACQUISITION CORP.**

By: /s/ Robert Chai-Onn  
Name: Robert Chai-Onn  
Title: Secretary

**VALEANT PHARMACEUTICALS  
INTERNATIONAL**

By: /s/ Robert Chai-Onn  
Name: Robert Chai-Onn  
Title: Executive Vice President, General Counsel  
and Corporate Secretary

**VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.**

By: /s/ Robert Chai-Onn  
Name: Robert Chai-Onn  
Title: Executive Vice President, General Counsel  
and Corporate Secretary

**EXHIBIT INDEX**

- (a)(1)(A) Offer to Purchase, dated March 26, 2013. \*
- (a)(1)(B) Form of Letter of Transmittal. \*
- (a)(1)(C) Form of Notice of Guaranteed Delivery. \*
- (a)(1)(D) Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. \*
- (a)(1)(E) Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. \*
- (a)(1)(F) Form of Internal Revenue Service Form W-9 (Request for Taxpayer Identification Number and Certification), including instructions for completing the form. \*
- (a)(2) Not applicable.
- (a)(3) Not applicable.
- (a)(4) Not applicable.
- (a)(5)(A) Press Release issued by Valeant Pharmaceuticals International, Inc. on March 20, 2013 (incorporated by reference to Exhibit (a)(5)(A) to the Tender Offer Statement on Schedule TO-C filed by Odysseus Acquisition Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc. with the Securities and Exchange Commission on March 20, 2013). \*
- (a)(5)(B) Form of Summary Advertisement. \*
- (a)(5)(C) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 3, 2013. \*
- (a)(5)(D) Letter to Obagi shareholders from Valeant Pharmaceuticals International, Inc. \*
- (a)(5)(E) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 22, 2013. \*
- (a)(5)(F) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 23, 2013. \*
- (a)(5)(G) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 24, 2013. \*
- (a)(5)(H) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 25, 2013.
- (b) Not applicable.
- (d)(1) Agreement and Plan of Merger, dated as of March 19, 2013, by and among Valeant Pharmaceuticals International, Odysseus Acquisition Corp., Valeant Pharmaceuticals International, Inc. and Obagi Medical Products, Inc. (incorporated by reference to Exhibit 2.1 to Obagi Medical Products, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2013). \*

- (d)(2) Amendment to Agreement and Plan of Merger, dated as of April 3, 2013, by and among Valeant Pharmaceuticals International, Odysseus Acquisition Corp., Obagi Medical Products, Inc. and Valeant Pharmaceuticals International, Inc. (incorporated by reference to Exhibit 2.1 to Obagi Medical Products, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2013). \*
- (g) Not applicable.
- (h) Not applicable.

\* Previously filed